CLDM 1% gel twice daily — Competitive Intelligence Brief

CLDM 1% gel twice daily (CLDM 1% gel twice daily) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lincosamide antibiotic. Area: Dermatology.

phase 3 Lincosamide antibiotic Bacterial 50S ribosomal subunit Dermatology Small molecule

Target snapshot

CLDM 1% gel twice daily (CLDM 1% gel twice daily) — GlaxoSmithKline. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CLDM 1% gel twice daily TARGET	CLDM 1% gel twice daily	GlaxoSmithKline	phase 3	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Erythromycin, Azithromycin , Clarithromycin	Erythromycin, Azithromycin , Clarithromycin	Baqiyatallah Medical Sciences University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin Ophthalmic Solution, 1%	Azithromycin Ophthalmic Solution, 1%	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
P.O roxithromycin 150 mg*2/d for 7 days	P.O roxithromycin 150 mg*2/d for 7 days	Western Galilee Hospital-Nahariya	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
PRISTINAMYCIN XRP7263	PRISTINAMYCIN XRP7263	Sanofi	marketed	Macrolide antibiotic / Streptogramin	Bacterial 50S ribosomal subunit
Altabax (R)	Altabax (R)	St. Luke's-Roosevelt Hospital Center	marketed	Pleuromutilin antibiotic	Bacterial 50S ribosomal subunit
Azithromycin Oral Product	Azithromycin Oral Product	Thomas Jefferson University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lincosamide antibiotic class)

1. GlaxoSmithKline · 2 drugs in this class
2. Balmoral Medical company · 1 drug in this class
3. Generic (originally Upjohn/Pfizer) · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Janssen-Cilag, S.A. · 1 drug in this class
6. Jinnah Postgraduate Medical Centre · 1 drug in this class
7. Oral and Maxillofacial Surgery Clinic, Poland · 1 drug in this class
8. Stiefel, a GSK Company · 1 drug in this class
9. Actavis Inc. · 1 drug in this class
10. University of Toronto · 1 drug in this class